Journal of Clinical Oncology
Articles in this Issue
<i>NOTCH1</i> Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial
PURPOSE Although multiple agents targeting PD-1 have been approved as second-line treatment for esophageal squamous cell carcinoma (ESCC), only a fraction of patients derive long-t...
Drug Shortages Demand Action: Policy Changes to Protect Patient Care
Reply to: Reflections on the HORSE Trial: Hyperthermic Intraperitoneal Chemotherapy, <i>BRCA</i> Status, and Clinical Implications
What I Wish I Had Known: A Pediatric Oncologist's Transition to Survivorship Care
This essay explores the often overlooked challenges of survivorship care, reflecting on the journey from pediatric oncology to supporting cancer survivors in navigating life after treatment.
Mid-Treatment Positron Emission Tomography–Adaptive Radiotherapy in Stage III Non–Small Cell Lung Cancer: Another Attempt Toward Personalized Care
Reflections on the HORSE Trial: Hyperthermic Intraperitoneal Chemotherapy, <i>BRCA</i> Status, and Clinical Implications
Maintenance Chemotherapy in Patients With High-Risk Rhabdomyosarcoma: Long-Term Survival Analysis of the European <i>Paediatric</i> Soft Tissue Sarcoma Study Group RMS 2005 Trial
The European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) RMS 2005 trial evaluated maintenance chemotherapy in high-risk rhabdomyosarcoma (RMS). Patients were randomly assigned to either discont...
Can Improving Adjuvant Endocrine Therapy Persistence Improve Survival Outcomes for Patients With Early-Stage Breast Cancer?
Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment
PURPOSE Survival for patients with melanoma has recently improved. The propensity of melanoma to metastasize to the brain remains a common and serious feature of this disease. The...
Reply to: Mid-Treatment Positron Emission Tomography–Adaptive Radiotherapy in Stage III Non–Small Cell Lung Cancer: Another Attempt Toward Personalized Care
Taletrectinib in <i>ROS1</i> + Non–Small Cell Lung Cancer: TRUST
PURPOSE Taletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI). We report integrated efficacy and safe...
Explaining the Relationships Between Age, Endocrine Therapy Persistence, and Risk of Recurrence in Hormone Receptor–Positive Early Breast Cancer: A Nationwide Cohort Study
PURPOSE Young age is associated with increased risk of recurrence in hormone receptor (HR)–positive early-stage breast cancer (eBC). Lack of adherence to endocrine therapy (ET) is a potent...
Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial
PURPOSE Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m 2 [4g/m 2...
Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer
PURPOSE Adjuvant endocrine therapy (ET) improves overall survival (OS) in estrogen receptor (ER)–positive early-stage breast cancer (BC). However, the benefit of ET for those with ER-low B...